Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer

Autor: Philip R. de Reuver, Wilhelmina M U van Grevenstein, Niels F. M. Kok, Daan D. Wisselink, Ignace H. J. T. de Hingh, Gaetano Gallo, Pieter J. Tanis, Linde L.F. Braakhuis, Susan van Dieren
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Oxaliplatin/therapeutic use
Survival
Colorectal cancer
Mitomycin/therapeutic use
colorectal cancer
cytoreductive surgery
HIPEC
mitomycin C
morbidity
oxaliplatin
peritoneal metastases
survival
0302 clinical medicine
Mitomycin C
Medicine
Cytoreductive surgery
Peritoneal Neoplasms
Colorectal Neoplasms/drug therapy
Cytoreduction Surgical Procedures
Hematology
Combined Modality Therapy
Oxaliplatin
030220 oncology & carcinogenesis
Meta-analysis
Hyperthermic intraperitoneal chemotherapy
Colorectal Neoplasms
medicine.drug
medicine.medical_specialty
Mitomycin
Antineoplastic Agents
03 medical and health sciences
Internal medicine
Journal Article
Humans
Hyperthermia
Comparative Study
business.industry
Induced
Antineoplastic Agents/therapeutic use
Postoperative complication
Hyperthermia
Induced
Peritoneal Neoplasms/drug therapy
medicine.disease
digestive system diseases
030104 developmental biology
Peritoneal metastases
Morbidity
business
Meta-Analysis
Zdroj: Critical Reviews in Oncology/Hematology, 142, 119. Elsevier Ireland Ltd
ISSN: 1040-8428
Popis: Background The role of hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin in addition to cytoreductive surgery (CRS) has recently been questioned in peritoneal metastases of colorectal cancer. Whether this applies to all published CRS/HIPEC regimens is unclear. Methods A systematic literature search identified 46 studies on CRS/HIPEC using either oxaliplatin of mitomycin C with at least one oncological outcome parameter Results Oxaliplatin and mitomycin C studies were comparable regarding extent of disease, but differed substantially regarding synchronous versus metachronous presentation, application of neo-adjuvant systemic chemotherapy, duration of HIPEC, and completeness of cytoreduction for at least one of the oncological endpoints. Severe postoperative complication rate seemed significantly higher after oxaliplatin-based CRS/HIPEC. Conclusion Published cohorts on oxaliplatin-based CRS/HIPEC differed essentially from MMC-based procedures, especially considering the application of oxaliplatin-containing neo-adjuvant systemic therapy and shorter exposure time to intraperitoneal chemotherapy in oxaliplatin studies. No meaningful comparison could be made regarding DFS and OS.
Databáze: OpenAIRE
Externí odkaz: